Human CellExp™ SARS-CoV-2 S1 (E484K), Recombinant

Biomolecule/Target: N/A

Synonyms: S1 Protein, Spike glycoprotein subunit1, S glycoprotein subunit1, SARS-CoV-2 S1 Protein

Alternates names: S1 Protein, Spike glycoprotein subunit1, S glycoprotein subunit1, SARS-CoV-2 S1 Protein

Taglines: A key protein in allowing viral entry into host cells

Taglines: USA

Country of Animal Origin: USA

NCBI Gene ID #.: 43740568

NCBI Gene Symbol: N/A

Gene Source: SARS-CoV-2

Accession #: P0DTC2

Recombinant: True

Source: HEK 293 cells

Purity by SDS-PAGE #: > 95% by SDS-PAGE

Assay: N/A

Purity: N/A

Assay #2: N/A

Endotoxin Level: N/A

Activity (Specifications/test method): N/A

Biological activity: N/A

Results: N/A

Binding Capacity: N/A

Unit Definition: N/A

Molecular Weight: ~120 kDa (8xHis tag at the C-terminus)

Concentration: N/A

Appearance: Lyophilized protein

Physical form description: Lyophilized powder

Reconstitution Instructions: Centrifuge the vial prior to opening. Reconstitute in sterile PBS (pH 7.4). Do not vortex.

Background Information: SARS-CoV-2, the causative virus of COVID-19, uses the viral Spike (S) protein for host cell attachment and entry. The virus uses multiple host targets including the human protease Furin, Angiotensin converting enzyme 2 (ACE2), Neuropilin-1 (NRP1) and the transmembrane protease serine 2 (TMPRSS2) for host cell entry. The S protein has two domains S1 and S2, where S1 facilitates initial binding to the receptor and the S2 domain drives the membrane fusion and eventual entry of the virus. The S glycoprotein serves as an important target for monoclonal antibodies, entry inhibitors, and vaccines. Within the S1 protein, the conserved receptor-binding domain (RBD) binds with a high affinity for ACE2. Recently, increasing concern has been garnered over the discovery of new SARS-CoV-2 variants with the ability to escape antibody-mediated protection either by previous infection or vaccination. The E484K mutation, which occurs in the RBD, is a substitution from a glutamic acid (E) to lysine (K) at position 484. It is one of the few mutations found in both the B.1.351 (South African) and P.1 (Brazil) strains. According to the CDC, they claim a moderate impact on neutralization by monoclonal antibody therapeutics and convalescent/post-vaccination sera for the E484K mutation. Furthermore, the South African strain is estimated to be roughly 50% more transmissible compared to other dominant lineages based on the rate of its spread.

Amino acid sequence: Val 16 - Arg 685

Handling: Centrifuge the vial prior to opening.

Usage: For Research Use Only! Not to be used in humans